Novo Nordisk’s Wegovy faces sharp decline in growth forecasts and share value as competition intensifies and compounded drug ...

As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...

Last year saw a dramatic rise in employees prescribed these drugs, officials said, driving up costs for Erie County's largest public health insurance consortium by an estimated $7.8 million. That ...

Kennedy has said that people who died from covid actually fell victim to chronic diseases such as obesity, diabetes, or asthma.

Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...